Clinical trial
UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma
NCT00083382 is registered in ClinicalTrials.gov with University of Arkansas as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma
- Lead sponsor
- University of Arkansas
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 1998
- Completion date
- May 31, 2014
- Enrollment
- 83 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.